UBS Sees 43% Upside in Tapestry, Eyes Wegovy Pill Blockbuster
UBS analysts upgraded Tapestry to Buy, forecasting a 43% upside driven by Coach’s share momentum and an AI-driven personalization edge. The firm also projects Novo Nordisk’s oral Wegovy GLP-1 therapy will reach blockbuster status by capturing significant market share in a crowded weight-loss treatment landscape.
1. UBS Upgrades Tapestry to Buy with 43% Upside
UBS analysts raised Tapestry’s rating to Buy, projecting a 43% upside based on Coach’s accelerated share momentum and strong same-store sales. The upgrade cites integration of AI-driven customer analytics to enhance personalization across digital and retail channels, supporting sustained revenue growth in leather goods.
2. Blockbuster Outlook for Novo Nordisk’s Oral Wegovy Pill
UBS research forecasts that the oral Wegovy GLP-1 therapy is poised to become a blockbuster weight-loss treatment, capable of capturing significant market share. Analysts highlight its differentiated delivery format and established brand equity as key advantages amid intensifying competition from multiple GLP-1 pipeline candidates.